Group 1: Restructuring Progress - The company is awaiting approval from the China Securities Regulatory Commission and the Supreme People's Court to enter the formal restructuring phase after signing the restructuring investment agreement with investors [1][2] - As of May 6, 2025, the recruitment and selection of restructuring investors have been successfully completed, with agreements signed with several investors [2] Group 2: Restructuring Plan and Investor Concerns - The restructuring plan has not yet been finalized, and the conversion date will be determined based on the restructuring plan [2] - Whether the restructuring will lead to a stock dilution will depend on the final equity adjustment plan, debt repayment price, and the stock market price at that time [2] - Currently, the industrial investors have not requested any asset injection into the company [2] Group 3: Investor Communication - The communication with investors was conducted through a text Q&A format, addressing concerns about governance, development strategy, operational status, and sustainability [1] - The restructuring investors are expected to settle in after the execution of the company's restructuring plan [2]
*ST长药(300391) - 300391*ST长药投资者关系管理信息20250613